MNCs Step Up Competition For China Tumor Drug Market
This article was originally published in PharmAsia News
Executive Summary
At the recent annual meeting of the American Society for Clinical Oncology, Bayer HealthCare released the Asia Pacific clinical trial results of its new drug Nexavar (sorafenib). This tumor drug represents the company's first to have its R&D conducted specifically for populations in China and Asia Pacific. Bayer officials say that due to China's huge potential in the tumor drug market, future product trials will consider Chinese patients and, if required, exclusive clinical tests will be carried out. Tumor drugs make up the fastest-growing segment within China's pharmaceutical market, spurring global drug giants to bring their latest offerings into the country. Nexavar was introduced to China only three months after it gained FDA approval in 2006. (Click here for more - Chinese Language)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.